AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- First patient has been dosed in Phase 1 pancreatic imaging study of RAD 301.
- The study aims at testing the safety and dosimetry of RAD 301.
- Under an investigator-initiated study, 99 patients have been imaged with RAD 301 previously, with no safety issues reported.
Triggered by the update, RAD shares jumped 16% to AU$0.065 apiece on 29 February 2024.
Radiopharm Theranostics Limited (ASX: RAD) has successfully dosed the first participant with pancreatic cancer in the Phase 1 study involving 68Ga-Trivehexin (RAD 301).
This trial focuses on evaluating the safety, imaging characteristics and radiation dosimetry of RAD 301 in patients with advanced Pancreatic Ductal Adenocarcinoma (PDAC), specifically targeting the αvβ6 integrin for detecting lesions relating to PDAC.
In May last year, the company obtained the FDA grant of an Orphan Drug Designation (ODD) for RAD 301 in pancreatic cancer.
The trial is being conducted at the Montefiore Medical Center, Albert Eistein College of Medicine, New York, the US.
Data source: Company update
Under an investigator-initiated study, RAD 301 has previously been used to image 99 patients, and no safety issues were reported.
RAD shares jumped
Following the update, RAD shares jumped ~16% to trade at AU$0.065 apiece at the time of writing on 29 February 2024.